INDICATIONS AND USAGE（适应症）

OLUMIANT® (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.

Limitation of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

DOSAGE（服用剂量）

The recommended dose of OLUMIANT is 2 mg once daily.

OLUMIANT may be used as monotherapy or in combination with methotrexate or other DMARDs.

OLUMIANT is given orally with or without food.

ADVERSE REACTIONS（不良反应）

Infections

Malignancy

Venous Thrombosis

Arterial Thrombosis

Platelet Elevations

Lipid Elevations

Nausea

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/866e9f35-9035-4581-a4b1-75a621ab55cf/spl-doc?hl=Baricitinib

Palutiniinformation